Sunday 18 October 2026
Export VTVT’s income statement to Excel — free account
vTv Therapeutics Inc.
VTVT Healthcare Biotechnology
In the quarter to June 2026, revenue grew 409,222.2%, EPS fell 14.1% and free cash flow fell 124.6%, each against the same quarter a year earlier.
26.54
1.05
−3.81%
Follow VTVT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(53.07%) | (68.52%) | 4.56% | (11.74%) | |
| (32.90%) | (42.09%) | 3.44% | (8.34%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(26.28%) | (32.40%) | 2.45% | (5.90%) | |
Average Days of Receivables |
— | — | 0.00 | — | |
Free Cash Flow per Share |
(2.59) | (3.00) | (0.84) | (1.35) | |
Free Cash Flow |
(20.83) | (25.25) | (10.41) | (16.76) | |
| Other line items | |||||
Cash ROIC |
(12.32%) | (16.47%) | (5.54%) | (10.14%) | |
Accounts Receivable Turnover |
— | — | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.14 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 63.41% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 41.92% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 11.49% | 0.00% | |
Interest Coverage |
(1,242.29) | (1,562.29) | — | — | |
Operating CF/Net income |
0.89 | 0.94 | (4.62) | 3.52 | |
Depreciation/Fixed assets |
2.57 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 3.05 | 0.00 | |
Operating CF per Share |
(2.59) | (3.00) | (0.84) | (1.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | — |
Columns are period end dates